Objective: This study aimed to discuss the clinical effects of pantoprazole and octreotide in upper gastrointestinal hemorrhage. Methods: A total of 114 patients with upper gastrointestinal hemorrhage admitted in our hospital from April 2016 to June 2017 were chosen and divided into control and experimental groups by lottery method. The control group (n=57) was treated with pantoprazole and the experimental group (n=57) was treated with pantoprazole+ octreotide. The therapeutic effect, occurrence rate of untoward effects, hemostatic effects at 24 and 72 h, blood-transfusion volume, hemostatic time and rehemorrhage rate at 48 h of the two groups were compared. Results: Compared with the control group, the experimental group exhibited significantly higher total therapeutic and hemostatic effects at 24 h, as well as lower occurrence rate of untoward effects and hemostatic effects at 24 h. Statistically significant differences were observed between the control and experimental groups (P<0.05). The experimental group had greater blood-transfusion volume, shorter hemostatic time and higher rehemorrhage rate at 48 h (P<0.05). Conclusion: The pantoprazole+ octreotide therapy exerted outstanding clinical effects on upper gastrointestinal hemorrhage. This combined therapy can decrease the occurrence rate of untoward effects and bloodtransfusion volume, reduce hemostatic time and prevent recurrent bleeding, thereby being worthy of clinical use and promotion.
INTRODUCTION
Upper gastrointestinal hemorrhage is a common emergency condition in clinical medicine. This condition can attack all age groups and it has a high occurrence rate of complications and mortality. 1 Upper gastro intestinal hemorrhage is the joint consequence of multiple complex and varying factors. Under normal conditions, gastric hemorrhage, acute hemorrhagic gastritis, MalloryWeiss syndrome and peptic ulcer are main causes of upper gastrointestinal hemorrhage. 2 Effective treatment lies in the timely fast hemostasis, reasonable selection of good hemostatic drugs and fast bleeding control. At present, conservative medication is the preferred choice of clinical therapy. 3 Thus, reasonable and effective ways of using medicines and treatments must be established to reduce mortality and improve the prog 
MATERIALS AND METHODS

General information
A total of 114 patients with upper gastro intestinal hemorrhage admitted in our hos pital from April 2016 to June 2017 were chosen. The inclusion standards were: This study was approved by the Ethics Commit tee of our hospital. All patients signed Informed Con sent forms after being informed about the goal of the study. The exclusion standards were: pregnant women and women in suckling period; patients with malignant tumors and blood diseases; patients with abnormal liver, kidney, heart and brain functions or with metal diseases; and patients with drug contraindications or drug allergy history. The patients were divided into the control and experimental groups through lottery method. 
Methods
Basic treatment was conducted as follows. After being admitted to the hospital, the patients were kept lying down under another person's assistance. The patients were forbidden to eat and oxygen uptake was offered immediately. Symptomatic treatment, including timing blood transfusion and transfusion, was implemented. In addition, nutrient supports were given and the protopathy was treated positively. At the same time, the blood pressure, heart rate, respiration, pulse, gastric tube drainage fluid and the fecal color and frequency of the patients were monitored closely. Stool routine examina tion, blood routine examination and hepatorenal function examination were performed regularly. The control group was treated with pantoprazole (SFDA approval number: H19990166, Hangzhou SinoAmerican Phar maceutical Co., Ltd., specification: chemical drug, 40 mg). An intravenous drip of 40 mg pantoprazole+100 mL 0.9% sodium chloride solution was given twice per day. Medication to patients with gastric cancer and renal insufficiency must be considered carefully. The experi mental group was given octreotide (SFDA approval number: H20090291, Jiangsu Osekang Pharmaceutical Co., Ltd., specification: chemical drug, 0.1 mg (counted at octreotide)) according to the treatment to the control group. An amount of 0.2 mg octreotide+20 mL 0.9% sodium chloride solution was intravenously pumped at 25-25 μg/h. The pumping rate was adjusted according to the amount of bleeding. This treatment was given continuously for three days. Blood transfusion was offered to patients with hemoglobin count of ≤70g/L.
Observation indices and evaluation of therapeutic effect
First, the hemostatic effects at 24 and 72 h of the two groups were evaluated according to following standards. The clinical symptoms were improved to some extent. The blood pressure and pulse recovered to the normal state. The gastric tube drainage fluid was cool. Gastros copy revealed that bleeding had stopped completely and new fresh bleeding signs were observed on the ulcer surface. Hematemesis disappeared and feces turned yel low. Occult blood test was negative and hemoglobin did not decline continuously. Effective hemostasis occurred if any one of these three standards was met and hemo stasis failure occurred if none was met. Second, the untoward effects in the two groups during the treatment were observed and recorded. Common untoward effects mainly included loss of appetite, dizzi ness, vomiting, retching, thirst, etc. Third, the hemostatic time, bloodtransfusion volume and rehemorrhage rate at 48 h were recorded. Fourth and last, therapeutic effect was classified according to the following evaluation standards: significantly effective: after 1 day of treatment, hemorrhage symptoms disap peared, systolic pressure (>90 mmHg) and diastolic pressure (>60 mmHg) recovered to normal standards and pulse>60 times/min; effective: after 1-3 days of treatment, hemorrhage symptoms disappeared, blood pressure and pulse recovered to the normal standards; and ineffective: live hemorrhage symptoms still existed after 3 days of treatment, blood pressure and pulse fluc tuated violently. Total therapeutic effect=significantly effective+ effective.
Statistical analysis
The data were analyzed by using SPSS 21.0. The measure ment data (e.g., hemostatic time and bloodtransfusion volume) were expressed as x -±s and examined by con ducting ttest. The enumeration data (e.g., total therapeutic effect, occurrence rate of untoward effects and hemo static effects) were expressed in % and examined by using X 2 test. P<0.05 indicated a statistically significant difference.
RESULTS
Therapeutic effects
The experimental group presented significantly higher total therapeutic effects than that of the control group (P<0.05). The results are shown in Table 1 .
Hemostatic effects
Compared with the control group, the experimental group showed higher hemostatic effect at 24 h but lower hemostatic effect at 72 h (P<0.05). The results are shown in Table 2 .
Blood-transfusion volume, hemostatic time and rehemorrhage rate at 48 h
The experimental group showed significantly lower bloodtransfusion volume, hemostatic time and rehem orrhage rate at 48 h than those of the control group (P<0.05). The results are shown in Table 3 .
Occurrence rate of untoward effects
The occurrence rate of untoward effects of the control group was 22.81%, which is significantly higher than that of the experimental group (7.02%) (P<0.05). The results are shown in Table 4 .
DISCUSSION
Upper gastrointestinal hemorrhage is a common critical disease in clinics. Its major symptoms include dizziness, hematemesis, melena and cold sweet. 4 This condition is characterized by the sudden onset, fast development, high mortality and serious threats to the life safety and physical health of patients. At present, external materials, surgical bypass and endoscope are the main clinical treatment procedures for upper gastrointestinal hemorrhage. 5 Among them, conservative medication is still the preferred choice. Inhibitors are common hemo static drugs for nonvaricosity upper gastrointestinal hemorrhage. It can reduce pepsin activity, accelerate thrombus freezing and prevent the proease damage, thus enabling to reach the expected hemostatic effects. 6, 7 However, the use of acid inhibitors alone cannot achieve satisfying hemostatic effects. Pantoprazole is a thirdgeneration protonpump inhibitor with strong target specificity and acid stability. It offers noncompetitive selective inhibition of the proton pump H + K + ATP enzyme in the cell membrane and interdict the final step of gastric acid secretion, thus effectively inhibiting gastric acid secretion and realizing hemostasis. 8, 9 As an octapeptide ring compound, octreotide is mainly synthesized artificially and it can develop the therapeutic effect of natural endogenous somatostatin. Octreotide is characterized by having strong effect and long duration. The halflife period of octreotide is more than 30 times that of natural demodicidin. 10 Octreotide can induces direct selective effects on vascular smooth muscles; significantly reduce the visceral blood flow; effectively inhibit the secretions of gastric acid, gastrin and protease; stimulate mucous secretion; protect the mucosal barrier; and recover mucous epithelial cells.
1112 More over, octreotide can increase the lower sphincter tension of the large esophagus, improve the gastric juice reflux, protect the esophagus mucosa and promote blood clot retraction and platelet aggregation. Octreotide offers outstanding therapeutic effects in alimentary tract hemorrhage, acute pancreatitis, intestinal obstruction and many other diseases.
CONCLUSION
In this study, significant differences were observed between the experimental and control groups in the total therapeutic effect, hemostatic effect at 24 h, occurrence rate of untoward effects and hemostatic effect at 72 h (P<0.05). The experimental group was superior to the control group in bloodtransfusion volume, hemostatic time and rehemorrhage rate at 48 h (P<0.05). These findings proved that the pantoprazole + octreotide combined therapy presented outstanding clinical effects in upper gastrointestinal hemorrhage. The proposed treatment can reduce the occurrence rate of untoward effects and bloodtransfusion volume, reduce hemo static time and prevent recurrent bleeding. As such, this strategy is worthy of clinical use and promotion.
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